Innocan Pharma Corp (INNO.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 26,612 | 29,437 | 13,657 | 2,559 | 196 |
| Cost of Goods | 2,681 | 3,250 | 1,679 | 452 | 75 |
| Gross Profit | 23,931 | 26,187 | 11,978 | 2,107 | 121 |
| Operating Expenses | 25,186 | 27,434 | 15,781 | 8,373 | 7,601 |
| Operating Income | -1,255 | -1,247 | -3,803 | -6,266 | -7,480 |
| Interest Expense | 3 | 7 | 0 | 2 | 13 |
| Other Income | 1,343 | 2,173 | -231 | 2,380 | -2,598 |
| Pre-tax Income | 85 | 919 | -4,034 | -3,888 | -10,091 |
| Income Tax | 426 | 1,181 | 214 | 1 | 0 |
| Net Income Continuous | -341 | -262 | -4,248 | -3,889 | -10,091 |
| Minority Interests | -783 | -1,572 | -452 | 125 | 44 |
| Net Income | $-1,124 | $-1,834 | $-4,700 | $-3,764 | $-10,047 |
| EPS Basic Total Ops | -0.25 | -0.65 | -1.11 | -1.04 | -3.25 |
| EPS Basic Continuous Ops | -0.25 | -0.65 | -1.11 | -1.04 | -3.25 |
| EPS Diluted Total Ops | -0.25 | -0.65 | -1.11 | -1.04 | -3.25 |
| EPS Diluted Continuous Ops | -0.25 | -0.65 | -1.11 | -1.04 | -3.25 |
| EBITDA(a) | $130 | $961 | $-4,001 | $-3,851 | $-10,035 |